Status:
COMPLETED
A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis
Lead Sponsor:
Moberg Pharma AB
Conditions:
Onychomycosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to further evaluate and document early visible effects on nail appearance of topical K101.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male or female patients aged 18 years or older
- 25%-75% of the target nail altered as a result of onychomycosis
- Signed written informed consent
- Exclusion criteria
- Proximal subungual onychomycosis
- Patient who has been previously randomized to treatment in the phase III study K70-2 investigating K101
- Other conditions known to cause abnormal nail appearance
- Use of topical (1 month before screening) and/or systemic (3 months before screening) antifungal medication.
- Participation in another clinical study with an investigational drug or device during the previous 4 weeks before enrolment.
- Known allergy to any of the tested treatment products
Exclusion
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT01180491
Start Date
September 1 2010
End Date
November 1 2010
Last Update
June 26 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.